Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Fri, 14 August 2026
What it is about
Mark KinarneyMary Anne HeinoKeith JohnsonAlzheimer AssociationDrug AdministrationHarvard Medical SchoolTerms Of ServiceExchange CommissionPharma SolutionsSecurities ExchangeManila, Manila, PhilippinesBedford, Massachusetts, United StatesUnited KingdomSwedenCanadaMassachusetts, United StatesNew Jersey, United StatesGermanySwitzerland
Who published it, and when
How it spread - 1 original report
Fri, 14 August 2026
1 report- manilatimes.net12:17first to report
BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ('Lantheus” or the 'Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in...